What were the findings of Mazdutide dose exploration in the U.S. population?
Significant weight loss in all dose groups at 32 weeks compared with placebo.[1] ↗
United States, 179 adults, randomized Phase II trial
Dose exploration and specific trial formulations.
View the Article Title and Full Citation+
Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial.
The Lancet. Diabetes & Endocrinology · Volume and issue year 2026
First published 2026-08-21 · PMID 42628555
DOI 10.1016/s2213-8587(26)00160-9







